CN115551831A - Cyp11a1抑制剂 - Google Patents

Cyp11a1抑制剂 Download PDF

Info

Publication number
CN115551831A
CN115551831A CN202180034328.3A CN202180034328A CN115551831A CN 115551831 A CN115551831 A CN 115551831A CN 202180034328 A CN202180034328 A CN 202180034328A CN 115551831 A CN115551831 A CN 115551831A
Authority
CN
China
Prior art keywords
compound
methylsulfonyl
methyl
alkyl
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180034328.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·丁贝尔
E·昆普莱宁
M·马科拉
P·皮耶迪凯宁
王守明
G·沃尔法特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of CN115551831A publication Critical patent/CN115551831A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
CN202180034328.3A 2020-05-14 2021-05-12 Cyp11a1抑制剂 Pending CN115551831A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20205486 2020-05-14
FI20205486 2020-05-14
PCT/FI2021/050353 WO2021229152A1 (en) 2020-05-14 2021-05-12 Cyp11a1 inhibitors

Publications (1)

Publication Number Publication Date
CN115551831A true CN115551831A (zh) 2022-12-30

Family

ID=76325569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180034328.3A Pending CN115551831A (zh) 2020-05-14 2021-05-12 Cyp11a1抑制剂

Country Status (8)

Country Link
US (1) US20230192677A1 (https=)
EP (1) EP4149924A1 (https=)
JP (2) JP7789697B2 (https=)
KR (1) KR20230010723A (https=)
CN (1) CN115551831A (https=)
AU (1) AU2021269872A1 (https=)
CA (1) CA3178067A1 (https=)
WO (1) WO2021229152A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024146383A1 (zh) * 2023-01-06 2024-07-11 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
WO2024199262A1 (zh) * 2023-03-29 2024-10-03 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2024199421A1 (zh) * 2023-03-30 2024-10-03 山东轩竹医药科技有限公司 Cyp11a1抑制剂
WO2024217531A1 (zh) * 2023-04-21 2024-10-24 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2025051216A1 (zh) * 2023-09-08 2025-03-13 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用
WO2025247149A1 (zh) * 2024-05-27 2025-12-04 辽宁海思科制药有限公司 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用
WO2026040949A1 (zh) * 2024-08-19 2026-02-26 辽宁海思科制药有限公司 一种cyp11a1抑制剂的药物组合物及其制备方法和用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117242056A (zh) * 2021-03-26 2023-12-15 北京加科思新药研发有限公司 用作sting激动剂的新型化合物及其用途
PE20241583A1 (es) * 2021-09-28 2024-08-01 Orion Corp Inhibidor de cyp11a1 para su uso en el tratamiento del cancer de prostata
WO2023084158A1 (en) * 2021-11-10 2023-05-19 Orion Corporation Cyp11a1 inhibitors
CN115304591B (zh) * 2022-07-08 2024-10-01 广州中医药大学(广州中医药研究院) 一种桥环甾体合成酶抑制剂及其制备方法和应用
AU2024270498A1 (en) * 2023-05-11 2025-11-27 Foshan Ionova Biotherapeutics Co., Inc. Novel compounds as cyp11a1 inhibitors and methods of use thereof
CN121605106A (zh) * 2023-07-27 2026-03-03 优领医药科技(香港)有限公司 Cyp11a1抑制剂
WO2026002207A1 (en) * 2024-06-28 2026-01-02 Acerand Therapeutics (Hong Kong) Limited Heterocyclic compounds as cyp11a1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471063A1 (en) 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
AR088320A1 (es) 2011-10-14 2014-05-28 Incyte Corp Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024146383A1 (zh) * 2023-01-06 2024-07-11 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
WO2024199262A1 (zh) * 2023-03-29 2024-10-03 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2024199421A1 (zh) * 2023-03-30 2024-10-03 山东轩竹医药科技有限公司 Cyp11a1抑制剂
WO2024217531A1 (zh) * 2023-04-21 2024-10-24 西藏海思科制药有限公司 Cyp11a1抑制剂及其用途
WO2025051216A1 (zh) * 2023-09-08 2025-03-13 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技（苏州）有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用
WO2025247149A1 (zh) * 2024-05-27 2025-12-04 辽宁海思科制药有限公司 一种cyp11a1抑制剂的盐及其晶型、其制备方法和应用
WO2026040949A1 (zh) * 2024-08-19 2026-02-26 辽宁海思科制药有限公司 一种cyp11a1抑制剂的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
EP4149924A1 (en) 2023-03-22
CA3178067A1 (en) 2021-11-18
KR20230010723A (ko) 2023-01-19
US20230192677A1 (en) 2023-06-22
JP7789697B2 (ja) 2025-12-22
AU2021269872A1 (en) 2022-11-24
JP2023525137A (ja) 2023-06-14
WO2021229152A1 (en) 2021-11-18
JP2026048803A (ja) 2026-03-17

Similar Documents

Publication Publication Date Title
CN115551831A (zh) Cyp11a1抑制剂
CN110139861B (zh) 作为cyp11a1(细胞色素p450单加氧酶11a1)抑制剂的吡喃衍生物
TWI761315B (zh) 醫藥化合物
CN114761412A (zh) 取代的大环化合物和相关治疗方法
AU2018391675A1 (en) Sulphonyl urea derivatives as NLRP3 inflammasome modulators
CN108473464B (zh) 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂
TW201827426A (zh) 具有ｇｌｐ－１受體促效作用的吡唑并吡啶衍生物
KR20160079091A (ko) 파르네소이드 x 수용체의 조정을 위한 조성물 및 방법
WO2022228547A1 (zh) 一种膦酰衍生物及其组合物和药学上的应用
TW201617340A (zh) 作為可溶性鳥苷酸環化酶活化劑的雜環羧酸
BRPI0708264A2 (pt) piperidinilpirrolidinas agonistas do receptor tipo 4 de melanocortina
KR20170005807A (ko) ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그
CN111868055A (zh) Trpc6的抑制剂
WO2022223039A1 (zh) Sos1降解剂及其制备方法和应用
TW202016084A (zh) 選擇性雌激素受體下調劑和其用途
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
TW202336011A (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
WO2022007903A1 (zh) 一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
CN114981270A (zh) Mll1抑制剂和抗癌剂
HK40093308A (zh) 作为cyp11a1抑制剂的吡喃衍生物
TW201910325A (zh) 吲哚衍生物及其用途
BR122024021737A2 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos
BR112019012906B1 (pt) Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination